Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD2 | P25440 | 13/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 13/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 13/20 | 0.37 |
| ▸ | BRD4 | O60885 | 12/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16259899 | 0.80 | BRD2 (0.36) | BRD2BRD3CREBBPBRD4SLC9A1 | |
| SCHEMBL16244381 | 0.77 | NQO2 (0.37) | BRD2BRD3CREBBPBRD4SLC9A1 | |
| SCHEMBL16268921 | 0.77 | TP53 (0.38) | BRD2BRD3CREBBPBRD4SLC9A1 | |
| SCHEMBL29343017 | 0.74 | BRD2 (0.35) | BRD2BRD3CREBBPBRD4SLC9A1 | |
| SCHEMBL27899640 | 0.72 | SLC9A1 (0.36) | BRD2BRD3CREBBPBRD4SLC9A1 | |
| SCHEMBL19330053 | 0.69 | MMP12 (0.38) | RPS6KA3KDM4ETSHRADORA2AADORA2B | |
| SCHEMBL24375535 | 0.68 | SLC9A1 (0.36) | SLC9A1KEAP1LMNAKDM4ETSHR | |
| SCHEMBL30036706 | 0.68 | SLC9A1 (0.50) | SLC9A1KEAP1LMNAKDM4ETSHR | |
| SCHEMBL256210 | 0.68 | SLC9A1 (0.50) | SLC9A1KEAP1LMNAKDM4ETSHR | |
| SCHEMBL16268461 | 0.68 | PRMT5 (0.39) | BRD2BRD3CREBBPBRD4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| US-9550796-B2 | Pyrrolopyrrolone derivatives and their use as BET inhibitors | NOVARTIS AG (CH) | 2017-01-24 | — | — | US | disclosed |
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | TPMT, REN, IL5 | BRD2 539/4885BRD3 492/4885CREBBP 2193/4885 |
| US-20160280719-A1 | PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS | BET1, PHKB, TMPO | BRD2 16/4885BRD3 12/4885CREBBP 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.